Search

Darapladib

Mebanazine

It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential. … Mebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals.

Lanolin alcohols

It is administered as an ointment base with topical insulin and has shown to be antagonistic to wound healing. It is commonly used in allergenic testing.

OPC-28326

It is the only clinical compound with this profile. It is currently being investigated in the treatment of peripheral vascular diseases and Raynaud's syndrome. … At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary

Binodenoson

This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion … Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A_2A receptor.

Alethine

It is a low molecular weight disulfide that has been shown to exhibit in vivo antitumor activity in murine myeloma and melanoma models. … Alethine is studied in the treatment of cancer. It belongs to a family of chemicals called disulfides.

FavId

FavId, is an active immunotherapy that is based upon unique genetic information extracted from a patient's tumor.

Clioquinol

Clioquinol was withdrawn in 1983 due to neurotoxicity.

Verubecestat

In the study, administration of Verubecestat at doses of 12, 40 and 60 mg resulted in a dose-dependent and sustained reduction in the levels of Ab40, a measure of BACE1 activity, in CSF from baseline of … In July 2013, Merck announced positive results for Phase Ib trials of Verubecestat.

VLTS-934

It was under investigation in clinical trial NCT00113009 (Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial Disease). … VLTS-934 was developed by Valentis inc. for the treatment of Peripheral Arterial Disease (PAD).